These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37143539)

  • 1. Traditional mineral medicine realgar and
    Luo L; Li C; Huang N; Wang Q; Zhang Z; Song C; Yang H; Yuan M; Xu Z; Sun J; Zhang Z
    Front Microbiol; 2023; 14():1143173. PubMed ID: 37143539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dissection of scientific compatibility of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia from the perspective of toxicology.
    Jiang Z; Sun Y; Wu Z; Tang M; Ye A; Tu B; Yi J; Xu H; Gao Y
    J Ethnopharmacol; 2023 Dec; 317():116895. PubMed ID: 37467822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influences of Realgar-
    Xu HH; Hao FR; Wang MX; Ren SJ; Li M; Tan HL; Wang YG; Tang XL; Xiao CR; Liang QD; Gao Y; Ma ZC
    Evid Based Complement Alternat Med; 2017; 2017():2374624. PubMed ID: 28421119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research on different compound combinations of Realgar-Indigo naturalis formula to reverse acute promyelocytic leukemia arsenic resistance by regulating autophagy through mTOR pathway.
    Li R; Xue C; Pan Y; Li G; Huang Z; Xu J; Zhang J; Chen X; Hou L
    J Ethnopharmacol; 2024 May; 326():117778. PubMed ID: 38310990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel realgar-indigo naturalis formula more effectively induces apoptosis in NB4 cells.
    Xie Q; Yu L; Wang X; Wu Z; Zhi D; Yang J; Guo Z; Wu T; Sun Y; Zhao L; Ding X; Khan A; Li H
    Pak J Pharm Sci; 2019 May; 32(3):957-962. PubMed ID: 31278706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral Realgar-Indigo Naturalis Formula Plus Retinoic Acid for Acute Promyelocytic Leukemia.
    Lou Y; Ma Y; Jin J; Zhu H
    Front Oncol; 2020; 10():597601. PubMed ID: 33614484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of clinical doses of Realgar-Indigo Naturalis formula and large-dose of realgar on CYP450s of rat liver].
    Xu HH; Wang MX; Tan HL; Wang YG; Tang XL; Xiao CR; Li H; Gao Y; Ma ZC
    Zhongguo Zhong Yao Za Zhi; 2017 Feb; 42(3):593-599. PubMed ID: 28952270
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of non-high-risk acute promyelocytic leukemia with realgar-indigo naturalis formula (RIF) and all-trans retinoid acid (ATRA): study protocol for a randomized controlled trial.
    Zhang X; Liu L; Yao Y; Gong S; Wang M; Xi J; Chen L; Wei S; Zhang H; Zhao C; Wang H
    Trials; 2020 Jan; 21(1):7. PubMed ID: 31898521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and the Adverse Effects of Oral Versus Intravenous Arsenic for Acute Promyelocytic Leukemia: A Meta-Analysis of Randomized-Controlled Studies.
    Sasijareonrat N; Jahn N; Ungprasert P; Owattanapanich W
    Technol Cancer Res Treat; 2020; 19():1533033820937008. PubMed ID: 32583728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The comparison of plasma arsenic concentration and urinary arsenic excretion during treatment with Realgar-Indigo naturalis formula and arsenic trioxide in children with acute promyelocytic leukemia.
    Liao LH; Chen YQ; Huang DP; Wang LN; Ye ZL; Yang LH; Mai HR; Li Y; Liang C; Luo JS; Wang LN; Luo XQ; Tang YL; Zhang XL; Huang LB
    Cancer Chemother Pharmacol; 2022 Jul; 90(1):45-52. PubMed ID: 35760920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption Characteristics of Combination Medication of Realgar and
    Zhang M; Guo L; Lin LF; Qu CH; Yin XB; Luo SL; Zhang X; Zhang HY; Liang X; Guan J; Ni J
    Evid Based Complement Alternat Med; 2018; 2018():6493630. PubMed ID: 30258467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indigo Naturalis Alleviates Dextran Sulfate Sodium-Induced Colitis in Rats via Altering Gut Microbiota.
    Sun Z; Li J; Dai Y; Wang W; Shi R; Wang Z; Ding P; Lu Q; Jiang H; Pei W; Zhao X; Guo Y; Liu J; Tan X; Mao T
    Front Microbiol; 2020; 11():731. PubMed ID: 32425906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study.
    Yang MH; Wan WQ; Luo JS; Zheng MC; Huang K; Yang LH; Mai HR; Li J; Chen HQ; Sun XF; Liu RY; Chen GH; Feng X; Ke ZY; Li B; Tang YL; Huang LB; Luo XQ
    Am J Hematol; 2018 Dec; 93(12):1467-1473. PubMed ID: 30160789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Arsenic Bioaccessibility of Realgar Influenced by the Other Traditional Chinese Medicines in Niuhuang Jiedu Tablet and the Roles of Gut Microbiota.
    Xu W; Xu S; Zhang S; Wu X; Jin P
    Evid Based Complement Alternat Med; 2019; 2019():8496817. PubMed ID: 31929821
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic Accumulation of Realgar Altered by Disruption of Gut Microbiota in Mice.
    Xu W; Zhang S; Jiang W; Xu S; Jin P
    Evid Based Complement Alternat Med; 2020; 2020():8380473. PubMed ID: 32908570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia.
    Wang L; Zhou GB; Liu P; Song JH; Liang Y; Yan XJ; Xu F; Wang BS; Mao JH; Shen ZX; Chen SJ; Chen Z
    Proc Natl Acad Sci U S A; 2008 Mar; 105(12):4826-31. PubMed ID: 18344322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Preliminary study of Realgar and arsenic trioxide on gut microbiota of mice].
    Sun YT; Xu HH; Nie Y; Wang YG; Ma ZC; Zhou W; Tan HL; Gao Y
    Zhongguo Zhong Yao Za Zhi; 2020 Jan; 45(1):142-148. PubMed ID: 32237423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical study on prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemia.
    Xiang-Xin L; Lu-Qun W; Hao L; Xiao-Peng H; Fang-Lin L; Ling-Ling W; Xue-Liang C; Ming H
    Evid Based Complement Alternat Med; 2014; 2014():987560. PubMed ID: 24963332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial.
    Zhu HH; Wu DP; Du X; Zhang X; Liu L; Ma J; Shao ZH; Ren HY; Hu JD; Xu KL; Wang JW; Song YP; Fang MY; Li J; Yan XY; Huang XJ
    Lancet Oncol; 2018 Jul; 19(7):871-879. PubMed ID: 29884593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of early switching to an outpatient therapy model using oral arsenic plus retinoic acid based-regimen in newly diagnosed acute promyelocytic leukemia.
    Lou Y; Tong H; Yu W; Wei J; Xu W; Mao L; Jin J
    Leuk Res; 2019 Aug; 83():106168. PubMed ID: 31202077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.